Avni Biron Irit, Maayan Yair, Mishael Tali, Hadar Eran, Neeman Michal, Plitman Mayo Romina, Sela Hen Y, Yagel Simcha, Goldenberg Rosalind, Ben Ya'acov Ami, Grisaru Granovsky Sorina, Ollech Jacob E, Edelman-Klapper Hadar, Rabinowitz Keren Masha, Pauker Maor H, Yanai Henit, Goren Sophy, Cohen Dani, Dotan Iris, Bar-Gil Shitrit Ariella
Inflammatory Bowel Disease Center, Division of Gastroenterology, Rabin Medical Center, Petah-Tikva 4919001, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 9436008, Israel.
Vaccines (Basel). 2022 Oct 29;10(11):1833. doi: 10.3390/vaccines10111833.
Regulatory agencies supported vaccination of pregnant women with SARS-CoV-2 mRNA vaccines, including patients with IBD. No data exist regarding these vaccines in IBD during pregnancy.
To assess the serologic response to two doses of the mRNA SARS-CoV-2 BNT162b2 vaccine in pregnant women with IBD vaccinated during pregnancy, compared to that of pregnant women without IBD, and non-pregnant women with IBD.
Anti-spike antibody levels were assessed in all women and in cord blood of consenting women.
From December 2020 to December 2021, 139 women were assessed: pregnant with IBD-36, pregnant without IBD-61, and not pregnant with IBD-42. Antibodies were assessed in cords of two and nine newborns of women with and without IBD, respectively. Mean gestational ages at administration of the second vaccine doses were 22.0 weeks in IBD and 23.2 weeks in non-IBD, respectively. Mean (SD) duration from the second vaccine dose to serology analysis in pregnant women with IBD, without IBD, and in non-pregnant women with IBD was 10.6 (4.9), 16.4 (6.3), and 4.3 (1.0) weeks, respectively. All women mounted a serologic response. In multivariable analysis, no correlation was found between the specific group and antibody levels. In both pregnancy groups, an inverse correlation between antibody levels and the interval from the second vaccine dose was demonstrated. Cord blood antibody levels exceeded maternal levels in women with and without IBD.
All patients with IBD mounted a serologic response. The interval between vaccine administration to serology assessment was the most important factor determining antibody levels. A third vaccine dose should be considered in pregnant women with IBD vaccinated at early stages of pregnancy.
监管机构支持为孕妇接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗，包括患有炎症性肠病（IBD）的患者。目前尚无关于孕期IBD患者接种这些疫苗的数据。
评估孕期接种两剂mRNA SARS-CoV-2 BNT162b2疫苗的IBD孕妇与未患IBD的孕妇以及非孕期IBD女性相比的血清学反应。
对所有女性及同意检测的女性的脐带血进行抗刺突抗体水平评估。
2020年12月至2021年12月，共评估了139名女性：患有IBD的孕妇36名、未患IBD的孕妇61名以及非孕期IBD女性42名。分别在2名患有IBD和9名未患IBD的女性的新生儿脐带血中检测了抗体。IBD患者和非IBD患者接种第二剂疫苗时的平均孕周分别为22.0周和23.2周。患有IBD的孕妇、未患IBD的孕妇以及非孕期IBD女性从接种第二剂疫苗到进行血清学分析的平均（标准差）时间分别为10.6（4.9）周、16.4（6.3）周和4.3（1.0）周。所有女性均产生了血清学反应。在多变量分析中，未发现特定组与抗体水平之间存在相关性。在两个孕期组中，均显示抗体水平与接种第二剂疫苗后的时间间隔呈负相关。无论是否患有IBD，脐带血抗体水平均超过母体水平。
所有IBD患者均产生了血清学反应。疫苗接种至血清学评估的时间间隔是决定抗体水平的最重要因素。对于在孕早期接种疫苗的IBD孕妇，应考虑接种第三剂疫苗。
